Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/178572
Title: | Apixaban for extended treatment of venous thromboembolism |
Author: | Agnelli, Giancarlo Buller, Harry R. Cohen, Alexander Curto, Madelyn Gallus, Alexander S. Johnson, Margot Porcari, Anthony Raskob, Gary E. Weitz, Jeffrey I. Riera Mestre, Antoni AMPLIFY-EXT Investigators |
Keywords: | Fibrinolítics Tromboembolisme Administració de medicaments Fibrinolytic agents Thromboembolism Administration of drugs |
Issue Date: | 8-Dec-2012 |
Publisher: | Massachusetts Medical Society |
Abstract: | Background: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. Methods: in this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months. Results: a total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. Conclusions: extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893). |
Note: | Reproducció del document publicat a: https://doi.org/10.1056/NEJMoa1207541 |
It is part of: | New England Journal of Medicine, 2012, vol. 368, num. 8, p. 699-708 |
URI: | http://hdl.handle.net/2445/178572 |
Related resource: | https://doi.org/10.1056/NEJMoa1207541 |
ISSN: | 0028-4793 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
661997.pdf | 412.34 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.